Medicare Supplement Plan (Rev 11/03/11) Page 11
amino acids and organic acids shall include food products modified to be low protein in
an amount not to exceed $5,000 annually for any Insured individual.
Where applicable, as required under M.G.L. c. 175, § 47G, as amended from time to time,
pap smear tests and mammograms not covered by Medicare.
Bone marrow transplants or transplants for certain patients with breast cancer as required
by M.G.L. c. 175, § 47M; M.G.L. c. 176A, § 8O (as added by St. 1993, c. 458, § 2); and
M.G.L. c. 176B, § 4O not covered by Medicare. The benefit described in 211 CMR
71.90(6) is subject to 211 CMR 71.06(4).
At the option of the Issuer, and if approved by the Commissioner, the New or Innovative
Benefits outlined in 211 CMR 71.09(1) or (5). Such New or Innovative Benefits may be
offered within the Policy or as an optional Alternate Innovative Benefit Rider to the
Medicare Supplement Core Insurance Policy.
________ Licensed hospice care services to terminally ill patients with a life expectancy of six
months or less, as set forth and regulated by M.G.L. c. 111, § 57D and as authorized by a
duly licensed physician as required by M.G.L. c. 175, § 47Q (as added by St. 1994, c. 284,
§ 2); M.G.L. c. 176A, § 8P (as added by St. 1994, c. 284, § 3); and M.G.L. c. 176B, § 4Q
(as added by St. 1994, c. 284, § 4).
Expenses incurred in the medically necessary diagnosis and treatment of speech, hearing
and language disorders individuals licensed as speech-language pathologists or
audiologists under M.G.L. c. 112, as required by M.G.L. c. 175, § 47U (as added by St.
2000, c. 345, § 2); M.G.L. c. 176A, § 8U (as added by St. 2000, c. 345, § 3); and M.G.L.
c. 176B, § 4U (as added by St. 2000, c. 345, § 4).
Hormone replacement therapy services for peri and post menopausal women and
outpatient contraceptive services under the same terms and conditions as for such other
outpatient services. Outpatient contraceptive services shall mean consultations,
examinations, procedures and medical services provided on an outpatient basis and related
to the use of all contraceptive methods to prevent pregnancy that have been approved by
the United States Food and Drug Administration, as required by M.G.L. c. 175, § 47W(a)
(as added by St. 2002, c. 49, §1); M.G.L. c. 176A, § 8W(a) (as added by St. 2002, c. 49,
§2); M.G.L. c. 176B, § 4W(a) (as added by St. 2002, c. 49, §3); and/or M.G.L. c.176G, §
4O(a) (as added by St. 2002, c. 49, § 4). The benefit described in 211 CMR 71.90(12) is
subject to 211 CMR 71.06(4).
________ According to M.G.L. c. 175 §47AA, M.G.L. c. 176A §8DD M.G.L. c. 176B §4DD fully
insured health plans issued or renewed by health insurance carriers on and after
January 1, 2011 must provide benefits for the diagnosis and treatment of ASD on a
nondiscriminatory basis to all residents of Massachusetts and to all insureds having a
principal place of employment in Massachusetts. [refer to above-noted statutes for a
complete description of the mandate]